88135-30-2

Basic information

• Product Name: 2,6-DICHLORO-4-NITROBENZENEACETONITRILE
• Synonyms: 2,6-DICHLORO-4-NITROBENZENEACETONITRILE
• CAS NO: 88135-30-2
• Molecular Formula: C₈H₄Cl₂N₂O₂
• Molecular Weight: 231.03556
• Mol File: 88135-30-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,6-DICHLORO-4-NITROBENZENEACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-4-NITROBENZENEACETONITRILE(88135-30-2)
• EPA Substance Registry System: 2,6-DICHLORO-4-NITROBENZENEACETONITRILE(88135-30-2)

Safety Data

• Hazardous Substances Data: 88135-30-2(Hazardous Substances Data)

Usage

General Description

2,6-Dichloro-4-nitrobenzeneacetonitrile is a chemical compound with the molecular formula C8H4Cl2N2O2. It is a yellow solid that is insoluble in water and is primarily used as an intermediate in the production of pharmaceuticals and agrochemicals. 2,6-Dichloro-4-nitrobenzeneacetonitrile is also a key building block in the synthesis of various complex organic molecules. However, 2,6-Dichloro-4-nitrobenzeneacetonitrile is known to be highly toxic and hazardous to human health, with potential risks of causing skin and eye irritation, as well as harm to the respiratory system. Therefore, proper handling and disposal procedures are necessary when working with this chemical.

Upstream product

• 17742-69-7 2,6-dichloro-4-nitro-anisole 
• 20098-48-0 3,4,5-trichloronitrobenzen 
• 105-56-6 ethyl 2-cyanoacetate 
• 35120-10-6 methylthioacetonitrile 
• 618-62-2 3,5-dichloro-1-nitrobenzene 
• 1116-98-9 cyanoacetic acid tert-butyl ester 

Downstream Products

• 261512-47-4 2,6-dichloro-α,α-dimethyl-4-nitrobenzeneacetonitrile 
• 88135-31-3 (2,6-dichloro-4-nitro-phenyl)-acetic acid 
• 920509-56-4 6-(4-(bromomethyl)-2,6-dichlorobenzyl)-4-isopropylpyridazin-3(2H)-one 
• 920509-57-5 [3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-ylmethyl)phenyl]acetonitrile 
• 920509-93-9 6-(4-amino-2,6-dichlorobenzyl)-4-isopropyl-2-methyl-2H-pyridazin-3-one 
• 920509-91-7 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)isoindoline-1,3-dione 
• 920509-92-8 2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)isoindoline-1,3-dione 
• 920509-49-5 ethyl (2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)hydrazineylidene)acetyl)carbamate 
• 920509-94-0 ethyl (2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenyl)hydrazono)acetyl)carbamate 
• 920509-51-9 2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1H-pyridazin-3-yl)methyl]phenyl]-3,5-dioxo-4H-1,2,4-triazine-6-carboxylic acid 
• 261943-91-3 2-(4-amino-2,6-dichlorophenyl)acetonitrile 
• 920509-47-3 2-(4-amino-2,6-dichloro-phenyl)-2-(6-chloro-5-isopropylpyridazin-3-yl)acetonitrile 
• 920509-48-4 6-[(4-amino-2,6-dichlorophenyl)methyl]-4-isopropyl-2H-pyridazin-3-one 
• 920509-55-3 6-(2,6-dichloro-4-hydroxymethylbenzyl)-4-isopropylpyridazin-3-one 

Relevant articles and documents

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

POLYCYCLIC COMPOUNDS AS ROR-GAMMA MODULATORS

The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.

NOVEL COMPOUNDS AS ROR-GAMMA MODULATORS

The present invention provides compounds which are modulators of ROR? and their use for the treatment of diseases or conditions mediated by ROR?. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, deuterated form, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them. formula (I)